脂质体伊立替康-话题@MedSci

#脂质体伊立替康#

3篇内容 | 1086人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2205358, encodeId=e5972205358b1, content=<a href='/topic/show?id=5e2e4e08988' target=_blank style='color:#2F92EE;'>#小细胞肺癌#</a> <a href='/topic/show?id=1c855620260' target=_blank style='color:#2F92EE;'>#拓扑替康#</a> <a href='/topic/show?id=2b7f8442613' target=_blank style='color:#2F92EE;'>#脂质体伊立替康#</a>, objectTitle=JCO | 脂质体伊立替康与拓朴替康治疗成人复发性小细胞肺癌的随机、开放标签Ⅲ期临床研究, objectType=article, longId=826358, objectId=d2c58263580e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240517/1715955785430_6145188.png, objectUrl=/article/show_article.do?id=d2c58263580e, replyNumber=0, likeNumber=12, createdTime=2024-05-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d2c58263580e, moduleTitle=JCO | 脂质体伊立替康与拓朴替康治疗成人复发性小细胞肺癌的随机、开放标签Ⅲ期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2c58263580e)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1299407, encodeId=6b9c129940efa, content=<a href='/topic/show?id=2b7f8442613' target=_blank style='color:#2F92EE;'>#脂质体伊立替康#</a>, objectTitle=Lancet Oncol：脂质体伊立替康联合亚叶酸和氟尿嘧啶或可成为晚期胆道癌的二线标准治疗方案！, objectType=article, longId=219153, objectId=574821915388, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=574821915388, replyNumber=0, likeNumber=48, createdTime=2021-10-25, rootId=0, userName=shalley66, userId=f378286, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=574821915388, moduleTitle=Lancet Oncol：脂质体伊立替康联合亚叶酸和氟尿嘧啶或可成为晚期胆道癌的二线标准治疗方案！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=574821915388)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1299406, encodeId=63281299406fd, content=<a href='/topic/show?id=2b7f8442613' target=_blank style='color:#2F92EE;'>#脂质体伊立替康#</a>, objectTitle=WCLC 2019：评估脂质体伊立替康（ONIVYDE）作为小细胞肺癌的二线疗法, objectType=article, longId=179176, objectId=99521e9176c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99521e9176c4, replyNumber=0, likeNumber=32, createdTime=2019-09-10, rootId=0, userName=shalley66, userId=f378286, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99521e9176c4, moduleTitle=WCLC 2019：评估脂质体伊立替康（ONIVYDE）作为小细胞肺癌的二线疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=99521e9176c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1299405, encodeId=dc741299405f5, content=<a href='/topic/show?id=2b7f8442613' target=_blank style='color:#2F92EE;'>#脂质体伊立替康#</a>, objectTitle=ESMO世界胃肠癌大会：评估脂质体伊立替康作为转移性胰腺癌一线疗法的I/II期临床研究, objectType=article, longId=174987, objectId=88ee1e49876f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88ee1e49876f, replyNumber=0, likeNumber=34, createdTime=2019-07-09, rootId=0, userName=shalley66, userId=f378286, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88ee1e49876f, moduleTitle=ESMO世界胃肠癌大会：评估脂质体伊立替康作为转移性胰腺癌一线疗法的I/II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88ee1e49876f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

脂质体伊立替康

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#小细胞肺癌# #拓扑替康# #脂质体伊立替康#

JCO | 脂质体伊立替康与拓朴替康治疗成人复发性小细胞肺癌的随机、开放标签Ⅲ期临床研究

2024-05-18发表于上海

shalley66 (审核中...)

前往app查看评论内容

#脂质体伊立替康#

Lancet Oncol：脂质体伊立替康联合亚叶酸和氟尿嘧啶或可成为晚期胆道癌的二线标准治疗方案！

2021-10-25

shalley66 (审核中...)

前往app查看评论内容

#脂质体伊立替康#

WCLC 2019：评估脂质体伊立替康（ONIVYDE）作为小细胞肺癌的二线疗法

2019-09-10

shalley66 (审核中...)

前往app查看评论内容

#脂质体伊立替康#

ESMO世界胃肠癌大会：评估脂质体伊立替康作为转移性胰腺癌一线疗法的I/II期临床研究

2019-07-09

科室
- - 订阅+
  - 更多科室
工具
服务